Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
ConditionMigraine Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOtsuka Pharmaceutical Co., Ltd.
About this trial
To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.
Eligibility criteria
Qualifiers
None
Disqualifiers
patients with a known hypersensitivity to components of AJOVY
Trial design
Treatments tested in this trial
- Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov